Skip Navigation


IJE Advance Access originally published online on April 11, 2007
International Journal of Epidemiology 2007 36(2):394-395; doi:10.1093/ije/dym023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
36/2/394    most recent
dym023v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Granich, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granich, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Commentary: Back to basics—good news from a birthplace of DOTS

Reuben Granich

Senior Technical Advisor, Care and Treatment, Program Services, Office of the United States Global AIDS Coordinator, 2100 Pennsylvania Avenue NW, Washington DC, USA.

E-mail: granichrm@state.gov

Accepted 30 January 2007

The first 10% of the full text of this article appears below.

Although India's tuberculosis (TB) control program has much to be pleased with, working on TB in India and elsewhere can be a daunting endeavour. The list of seemingly insurmountable global challenges is off-putting, to say the least: 8.9 million new TB cases each year; 1.7 million TB deaths annually, despite the existence of an effective cure; a devastating HIV/AIDS pandemic; archaic diagnostic technology often dating back to the early 1900s; pitiable investments in public health infrastructure; and now—the latest grim news regarding extensively drug resistant (XDR) TB, make for very heavy sledding.1–4

XDR-TB is particularly alarming in the context of the HIV/AIDS pandemic. Early reports suggest a TB mortality rate . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?